TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.MarketBeat
- City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and ExpositionGlobeNewswire
TCRX
Earnings
- 11/12/24 - Beat
TCRX
Sec Filings
- 12/16/24 - Form 4
- 12/10/24 - Form 8-K
- 11/21/24 - Form 8-K
- TCRX's page on the SEC website